The story of Sildenafil presents a intricate picture for shareholders. While the initial launch generated massive gains, the expiration of its patent opened the door to off-brand competitors, dramatically reducing https://bookmarkassist.com/story21523061/the-copyright-and-big-pharma-a-risky-bet